Short answer · Medically reviewed summary · Last updated: 2026-05-08
Essential Thrombocythemia is a chronic blood cancer characterized by the bone marrow overproducing too many platelets, primarily driven by acquired somatic genetic mutations. While the exact trigger for these mutations remains under investigation, the condition is not considered hereditary, as the underlying genetic changes occur spontaneously in the individual's blood-forming cells. What are the primary genetic causes of Essential Thrombocythemia? The development of Essential Thrombocythemia is largely attributed to acquired mutations in specific genes that regulate cell signaling.
2 people with Essential Thrombocythemia have shared their first-person experience on this question at DiseaseMaps.
Which are the causes of Essential Thrombocythemia?
Causes of Essential Thrombocythemia explained: genetic and environmental factors, reviewed against medical sources, plus patient perspectives.
Essential Thrombocythemia is a chronic blood cancer characterized by the bone marrow overproducing too many platelets, primarily driven by acquired somatic genetic mutations. While the exact trigger for these mutations remains under investigation, the condition is not considered hereditary, as the underlying genetic changes occur spontaneously in the individual's blood-forming cells.
What are the primary genetic causes of Essential Thrombocythemia?
The development of Essential Thrombocythemia is largely attributed to acquired mutations in specific genes that regulate cell signaling. These mutations act like a "stuck accelerator" in the bone marrow, causing it to produce an excess of platelets. Research shows that approximately 90% of patients with Essential Thrombocythemia carry one of three main "driver" mutations:
- JAK2 (Janus Kinase 2): Found in about 50–60% of Essential Thrombocythemia cases.
- CALR (Calreticulin): Present in 20–25% of patients.
- MPL (Myeloproliferative Leukemia virus oncogene): Found in 3–5% of cases.
Are these mutations hereditary?
No, Essential Thrombocythemia is not an inherited condition. The mutations associated with Essential Thrombocythemia are somatic, meaning they occur in the DNA of the blood-forming stem cells during a person's lifetime. They are not passed down from parents to children, and there is no known way to prevent these random genetic errors from occurring.
What is the difference between causes and risk factors in Essential Thrombocythemia?
A "cause" refers to the direct biological mechanism—in this case, the somatic mutation—that forces the bone marrow to overproduce platelets. In contrast, "risk factors" are broader influences. While age is a significant risk factor, with most diagnoses occurring after age 60, environmental or lifestyle triggers are not definitively linked to the onset of Essential Thrombocythemia. Unlike some cancers, there is no evidence that diet, chemical exposure, or lifestyle choices cause this specific disease.
What does current research suggest about the etiology of Essential Thrombocythemia?
Current research into Essential Thrombocythemia is focused on identifying why these specific mutations arise and how they interact with the bone marrow microenvironment. Scientists are exploring "clonal hematopoiesis of indeterminate potential" (CHIP), where older individuals develop small populations of mutated blood cells that may eventually evolve into Essential Thrombocythemia. Understanding these early stages is a major priority for clinical researchers aiming to improve early detection and treatment.
Next steps
- Consult a hematologist to discuss your specific genetic mutation status (JAK2, CALR, or MPL).
- Join the 325 members on DiseaseMaps.org to share experiences and find support for managing symptoms like fatigue and bone pain.
- Ask your physician about clinical trials investigating targeted therapies that may offer alternatives to standard medications like Hydrea.
Medical disclaimer: This information is for educational purposes only and does not constitute medical advice, diagnosis, or treatment; always seek the advice of your physician regarding a medical condition.
References
- NIH Genetic and Rare Diseases Information Center (GARD): Essential Thrombocythemia.
- Orphanet: Essential Thrombocythemia (ORPHA:3335).
- OMIM (Online Mendelian Inheritance in Man): Thrombocythemia, Essential (Entry #187950).
- MPN Research Foundation: Understanding Essential Thrombocythemia.
However, researchers have discovered mutations that alter the activity of proteins that control signaling pathways (important regulators of cell growth and development) in many patients with ET. Signaling pathways are important regulators of cell growth and development.
As mentioned before cause of ET is not fully understood. About half of
patients with ET have a mutation of the JAK2 (Janus kinase 2)
gene in their blood cells. Whether or not a patient has the
mutation does not appear to significantly affect the nature
or course of the disease. Research is under way to determine
the precise role of the JAK2 mutation in the biology of the
disease and to identify other mutations in ET patients.
The incidence (newly diagnosed cases) of ET for all races
and ethnicities is approximately 2.2 per 100,000 population
each year. ET occasionally occurs in older children, but is
mostly diagnosed in adult men and women. The prevalence
(estimated number of people alive on a certain date in a
population with a diagnosis of the disease) is approximately
24 cases per 100,000 population, which has been shown in
several small studies.
Posted Aug 11, 2017 by Steve 2685
Posted Feb 7, 2019 by James 3550
